Get the Stockscreener App
2.68
1.47%
-0.04
Pre-market:
2.52
-0.16
-5.97%
Aerovate Therapeutics Inc stock is traded at $2.68, with a volume of 1.10M.
It is down -1.47% in the last 24 hours and up +6.77% over the past month.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
See More
Previous Close:
$2.72
Open:
$2.67
24h Volume:
1.10M
Relative Volume:
4.43
Market Cap:
$80.29M
Revenue:
-
Net Income/Loss:
$-75.52M
P/E Ratio:
-0.9306
EPS:
-2.88
Net Cash Flow:
$-56.92M
1W Performance:
-2.55%
1M Performance:
+6.77%
6M Performance:
+26.42%
1Y Performance:
-87.58%
1-Day Range:
$2.57
$2.69
1-Week Range:
$2.57
$2.86
52-Week Range:
$1.25
$25.29
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Name
Aerovate Therapeutics Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare AVTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
2.68 | 80.29M | 0 | -75.52M | -56.92M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Aerovate Therapeutics Inc Stock (AVTE) Latest News
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate approves reverse split ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics and Jade Biosciences Merger Approved - citybiz
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate (AVTE) Stockholders Approve Merger with Jade Biosciences | AVTE Stock News - GuruFocus
Aerovate Therapeutics Approves Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals - PR Newswire
Aerovate announces $69.6 million special dividend By Investing.com - Investing.com India
Aerovate announces $69.6 million special dividend - Investing.com Australia
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
Aerovate signals cash dividend ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics Stock Bucks Broader Market Sell-Off Over Dividend Announcement: Stock Rises But Retail’s Unmoved - NewsBreak: Local News & Alerts
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - MarketScreener
Aerovate Therapeutics Announces Merger with Jade Biosciences - TipRanks
Aerovate signals cash dividend ahead of Jade merger - Investing.com
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
36,897 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Acquired by Corient Private Wealth LLC - Defense World
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AMPY, HEES, AVTE, TGI to Act - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AV - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Urges Stockholders of AMPY, HEES, AVTE, TGI to Act Now - GlobeNewswire Inc.
Aerovate Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aerovate Therapeutics Inc. (AVTE) reports earnings - Quartz
Aerovate Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc.AVTE - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PTMN, AVTE on Behalf of Shareholders - The Malaysian Reserve
Aerovate Therapeutics (AVTE) Expected to Announce Quarterly Earnings on Monday - Defense World
FY2029 Earnings Estimate for AVTE Issued By Wedbush - MarketBeat
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE, BMTX, PFIE, ALTR on Behalf of Shareholders - ACCESS Newswire
FY2029 Earnings Forecast for AVTE Issued By Wedbush - Defense World
In Another Blow to Delaware's Hegemony Another Company Proposes Reincorporation in Nevada - NatLawReview.com
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The MergerCCNE, LGTY, AVTE, PLYA - Longview News-Journal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, AVTE, BLUE on Behalf of Shareholders - Stockhouse Publishing
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Increase in Short Interest - MarketBeat
Ready to Jump After Recent Trade: Aerovate Therapeutics Inc (AVTE) - SETE News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IVAC, AVTE, QTRX on Behalf of Shareholders - EIN News
Deltec Asset Management LLC Invests $514,000 in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - MarketBeat
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Growth in Short Interest - MarketBeat
Barclays PLC Raises Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates MHLD, IPG, AVTE on Behalf of Shareholders - GlobeNewswire
Aerovate Therapeutics Inc Stock (AVTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):